|
1
|
Zumwalt TH and Goel A: Immunotherapy of
metastatic colorectal cancer: prevailing Challenges and new
perspectives. Curr Colorectal Cancer Rep. 11:125–140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang H and Huang B: Tumor cell-derived
microparticles: a new form of cancer vaccine. Oncoimmunology.
4:e10177042015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Onji M and Akbar SMF: On dendritic cell
based therapy for cancers. Zhejiang Univ Sci B. 6:1–3. 2005.
View Article : Google Scholar
|
|
4
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gu F: Epidemiological survey of benign
prostatic hyperplasia and prostate cancer in China. Chin Med J
(Engl). 113:299–302. 2000.In Chinese.
|
|
6
|
Basler M and Groettrup M: Advances in
prostate cancer immunotherapies. Drugs & Aging. 24:197–221.
2007. View Article : Google Scholar
|
|
7
|
Murphy GP, Tjoa BA, Simmons SJ, Jarisch J,
Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, et al:
Infusion of dendritic cells pulsed with HLA-A2-specific
prostate-specific membrane antigen peptides: A phase II prostate
cancer vaccine trial involving patients with hormone-refractory
metastatic disease. Prostate. 38:73–78. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murphy GP, Tjoa BA, Simmons SJ, Rogers MK,
Kenny GM and Jarisch J: Higher-dose and less frequent dendritic
cellinfusions with PSMA peptides in hormone-refractory metastatic
prostate cancer patients. Prostate. 43:59–62. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou Y, Wang HP and Wang Q: Advances in
design strategy of dendritic cell vaccine. Medical Journal of
Chinese People's Liberation Army. 31:1205–1206. 2006.In
Chinese.
|
|
10
|
Ribas A, Butterfield LH, Glaspy JA and
Economou JS: Cancer immunotherapy using gene-modified dendritic
cells. Curr Gene Ther. 2:57–78. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Q, Xia D, Carlsen S and Xiang J:
Adenovirus-mediated transgene-engineered dendritic cell vaccine of
cancer. Curr Gene Ther. 5:237–247. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perner S, Hofer MD, Kim R, Shah RB, Li H,
Möller P, Hautmann RE, Gschwend JE, Kuefer R and Rubin MA: Prostate
specific membrane antigen expression as a predictor of prostate
cancer progression. Hum Pathol. 38:696–701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang P, Chiu YC, Tostanoski LH and Jewell
CM: Polyelectrolyte multilayers assembled entirely from immune
signals on gold nanoparticle templates promote antigen-specific T
cell response. ACS Nano. 9:6465–6477. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu K, Yu B, Huang H, Zhang P, Ji L and
Chao H: Tetranuclear ruthenium(II) complexes with oligo-oxyethylene
linkers as one-and two-photon luminescent tracking non-viral gene
vectors. Dalton Trans. 44:7058–7065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xia D, Moyana T and Xiang J: Combinational
adenovirus-mediated gene therapy and dendritic cell vaccine in
combating well-established tumors. Cell Res. 16:241–259. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Yan and Shen Xi: The impact of
transfection with common viral vector on dendritic cells. Foreign
Medical Science (Molecular Biology Section). 25:188–190. 2003.In
Chinese.
|
|
17
|
Liu Qingxin and Song Jun: Viral
vector-mediated gene therapy for prostate cancer. International
Journal of Urology and Nephrology. 20:62–63. 2000.In Chinese.
|
|
18
|
Slovin SF, Kehoe M, Durso R, Fernandez C,
Olson W, Gao JP, Israel R, Scher HI and Morris S: A phase I dose
escalation trial of vaccine replicon particles (VRP) expressing
prostate-specific membrane antigen (PSMA) in subjects with prostate
cancer. Vaccine. 31:943–949. 2013. View Article : Google Scholar
|
|
19
|
Wang W and Mo ZN: Advances in
prostate-specific membrane antigen targeted therapies for prostate
cancer. Zhonghua Nan Ke Xue. 16:547–551. 2010.In Chinese.
PubMed/NCBI
|
|
20
|
Medin JA, Liang SB, Hou JW, Kelley LS,
Peace DJ and Fowler DH: Efficient transfer of PSA and PSMA cDNAs
into DCs generates antibody and T cell antitumor responses in vivo.
Cancer Gene Ther. 12:540–551. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeng H, Wu Q, Li H, Wei Q, Lu Y, Li X,
Wang F, Zhao F, Ding Z and Yang Y: Construction of
prostate-specific expressed recombinant plasmids with high
transcriptional activity of prostate-specific membrane antigen
(PSMA) promoter/enhancer. J Androl. 26:215–221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Q, Zaiss AK, Colarusso P, Patel K,
Haljan G, Wickham TJ and Muruve DA: The role of capsid-endothelial
interactions in the innate immune response to adenovirus vectors.
Hum Gene Ther. 14:627–643. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Philpott NJ, Nociari M, Elkon KB and
Falck-Pedersen E: Adenovirus-induced maturation of dendritic cells
through a PI3 kinase-mediated TNF-alpha induction pathway. Proc Nat
Acad Sci USA. 101:6200–6205. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smyth MJ, Godfrey DI and Trapani JA: A
fresh look at tumor immunosurveillance and immunotherapy. Nat
Immunol. 2:293–299. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan Y and Moon JJ: Nanoparticle drug
delivery systems designed to improve cancer vaccines and
immunotherapy. Vaccines. 3:662–685. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu A, Takahashi M, Narita M, Zheng Z,
Kanazawa N, Abe T, Nikkuni K, Furukawa T, Toba K, Fuse I and Aizawa
Y: Generation of functional and mature dendritic cells from cord
blood and bone marrow CD34+ cells by two-step culture combined with
calcium ionophore treatment. J Immunol Methods. 261:49–63. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hill JA, Ichim TE, Kusznieruk KP, Li M,
Huang X, Yan X, Zhong R, Cairns E, Bell DA and Min WP: Immune
modulation by silencing IL-12 production in dendritic cells using
small interfering RNA. J Immunol. 171:691–696. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weigel BJ, Panoskaltsis-Mortari A, Diers
M, Garcia M, Lees C, Krieg AM, Chen W and Blazar BR: Dendritic
cells Pulsed or fused with AML cellular antigen provide comparable
in vivo antitumor protective responses. Exp Hematol. 34:1403–1412.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rivoltini L, Castelli C, Carrabba M,
Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen
C, Squarcina P, et al: Human tumor-derived heat shock protein 96
mediates in vitro activation and in vivo expansion of melanoma- and
colon carcinoma-specific T cells. J Immunol. 171:3467–3474. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mazzaferro V, Coppa J, Carrabba MG,
Rivoltini L, Schiavo M, Regalia E, Mariani L, Camerini T, Marchianò
A, Andreola S, et al: Vaccination with autologous tumor-derived
heat-shock protein gp96 after liver resection for metastatic
colorectal cancer. Clin Cancer Res. 9:3235–3245. 2003.PubMed/NCBI
|
